BioRegenx, Inc.
BRGX
$0.01
-$0.0039-28.06%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 83.88% | 91.53% | -7,068.13% | 84.32% | -86.06% |
| Total Depreciation and Amortization | -93.44% | -97.52% | 47,775.00% | 47,775.00% | 47,375.00% |
| Total Amortization of Deferred Charges | -108.82% | -86.61% | -- | -- | -- |
| Total Other Non-Cash Items | -60.78% | -96.02% | 6,604.94% | -111.64% | -- |
| Change in Net Operating Assets | -51.43% | -18.69% | 155.09% | 1,102.44% | 290.20% |
| Cash from Operations | 101.80% | 136.15% | 95.36% | 88.99% | 72.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 101.35% | -- | -- |
| Cash from Investing | -- | -- | 101.35% | -- | -- |
| Total Debt Issued | -77.29% | -- | -42.31% | -20.22% | 16,612.50% |
| Total Debt Repaid | -10.00% | 40.23% | 48.17% | 43.72% | -200.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -86.01% | -103.68% | -101.34% | -60.03% | -70.66% |
| Foreign Exchange rate Adjustments | -1,540.00% | -310.00% | 544.44% | -- | -96.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 34.51% | 325.00% | -117.36% | 107.59% | 74.65% |